Answers are grounded in this paper and cite their sources.
Introduction Hypoxia‐inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) are widely used to treat renal anemia, but their effects on peritoneal injury during peritoneal dialysis remain poorly understood. We investigated the impact of enarodustat, an HIF‐PHI, on peritoneal injury and fibrosis. Methods Peritoneal injury was induced in 8‐week‐old Sprague–Dawley rats by mechanical scraping. Those rats were randomized to receive vehicle or enarodustat (0.3 or 3.0 mg/kg) once daily by oral gavage for 7 days or 14 days. On Days 7 and 14, the parietal peritoneum was evaluated histologically and immunobiologically for thickening, fibrosis, and inflammatory cell infiltration. Protein and mRNA expression levels from peritoneal tissue were quantified. Results Enarodustat did not significantly increase peritoneal thickness, fibrosis, inflammatory infiltration, or markers of fibrosis or inflammation compared with vehicle on either day, although red blood cell counts increased. Conclusion Enarodustat did not aggravate peritoneal inflammation or fibrosis in this short‐term experimental model.
No takes yet. Share an insight, caveat, or question.
Ototake et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: